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j Abstract Background The
analysis of markers in the cere-
brospinal ﬂuid (CSF) is useful in
the diagnosis of sporadic Creutz-
feldt-Jakob disease (sCJD). How-
ever, the time at which the study
of these markers is most sensitive
remains controversal. Objective
To assess the inﬂuence of time of
sampling on the value of CSF tests
in the diagnosis of sCJD. Method
In the framework of a multina-
tional European study, we studied
the results of 14-3-3, S100b, neu-
rone speciﬁc enolase (NSE) and
tau protein in 833 CSF samples
from sCJD patients at different
stages of disease and in 66
sequentially repeated lumbar
punctures (LP). Results 14-3-3
and tau protein tended to increase
in sensitivity from onset (88%,
81%) to the advanced stage (91%,
90%). This was signiﬁcant only in
the methionine-valine (MV) het-
erozygous group of patients at
codon 129. The absolute levels of
S100b (p < 0.05), NSE and tau
protein increased in the last stage
of disease. High levels of tau
protein, NSE and S100b were
associated with shorter survival
times (p < 0.01). Sixty-six sCJD
patients underwent repeated LP.
These sCJD patients were younger,
had longer disease durations and
were more frequently MV at
codon 129 (p < 0.001) than the
whole group. 14-3-3 sensitivity
increased from 64% to 82% in the
second LP (p = 0.025) and 88%
sCJD patients had at least one
positive result. Conclusions Sen-
sitivity and absolute levels of CJD
markers increased with disease
progression and were modulated
by the codon 129 genotype. Early
negative results should be inter-
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Creutzfeldt-Jakob disease (CJD) is a rapidly pro-
gressive neurodegenerative disease. Presently, the
deﬁnite diagnosis of CJD requires neuropathological
conﬁrmation. Cerebrospinal ﬂuid (CSF) analysis
plays an important role in the diagnosis of CJD.
After the WHO consultation in 1998, a positive 14-3-
3 result is considered as a criterion of probable
sporadic CJD (sCJD) [12]. Different studies have
shown that in the appropriate clinical circumstances
a positive 14-3-3 is highly sensitive and speciﬁc for
the diagnosis of sCJD [14]. However, the question
remains open as to whether 14-3-3 is more sensitive
in the initial or late stages of disease. Increased
levels of other brain-derived proteins, such as
microtubule-associated tau protein [8], S100b [4] or
neurone speciﬁc enolase (NSE) [13] have also been
reported to be elevated in CSF in CJD. The published
data about how the levels of these proteins are
modiﬁed during the course of disease are contra-
dictory [1–3, 5–7, 10, 11]. In addition, the time point
during the disease, when biochemical markers are
expected to have the highest sensitivity, is not well-
deﬁned. These topics have not been studied sys-
tematically, especially because data from sequential
CSF analyses are rarely available.
In the framework of an European Community
supported multinational study on CJD markers, we
performed an analysis of the results obtained in
different stages of the disease and in repeated lum-
bar punctures (LP) to assess the inﬂuence of time of
sampling on the value of CSF tests in the diagnosis
of sCJD.
Methods
j Study overview
This study was conducted in the framework of a European Com-
munity supported multinational study (Early clinical diagnosis
of human spongiform encephalopathies by analysis of biological
ﬂuids (CJDmarkers), (QLG3-CT-2002-81606 Coordinator: I. Zerr).
All participant countries belong to the EUROCJD Surveillance
network with comparable surveillance methods. CSF samples were
sent to the individual laboratories for 14-3-3 analysis in the par-
ticipating countries between 1998–2003 and clinical and patho-
logical data were collected. CSF was obtained by LP and the
analyses were conducted in each laboratory following standard
protocols [9]. An analysis of test validity and comparability be-
tween laboratories revealed high agreement between laboratories
[9]. Previously published cut-off values were used for the quanti-
tative markers [8, 13].
In all countries, clinical and neuropathological data from pa-
tients with clinical suspicion of CJD or related disorders were
collected. The diagnoses of CJD and various CJD subtypes were
made according to the established criteria in all participating
centers. Core clinical data such as age at onset, gender, disease
duration, time point of the LP, codon 129 genotype, PrP
res type and
ﬁnal clinical and neuropathological diagnoses were centralized by
each center. A database was set up, which included detailed data on
the CSF markers and patients’ characteristics. The study was per-
formed in accordance with the ethical standards laid down in the
1964 Declaration of Helsinki.
j Statistical analyses
Since the clinical duration within sCJD patients varies widely
depending upon several variables (e.g., age at onset, gender, codon
129 polymorphism of the PRNP gene, and PrP
res type), the time
interval between LP and disease onset is not an appropriate esti-
mate of the stage of disease when the LP was performed. To
overcome this problem, we divided the time of LP to disease onset
in each patient by the total duration of the disease. Thus, we
classiﬁed patients in three categories according to whether they
preted with caution, especially in
young patients or those who are
MV at codon 129.
j Key words Creutzfeldt-Jakob
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902underwent LP in the ﬁrst (time of LP to disease onset/ total dura-
tion of the disease < 0.33), second (0.33–0.66) or third (>0.66)
stage of the disease. We analyzed the sensitivity of each marker at
different stages of the disease. The differences in sensitivities across
strata were analyzed using a logistic regression model adjusting for
possible confounders and covariates. We also performed a stratiﬁed
analysis by codon 129 PRNP genotype. In a similar way we assessed
the absolute levels of quantitative markers across the different
stages of the disease. The absolute levels of S100b obtained with
different methods were analysed separately.
In order to evaluate the correlation between tau protein, S100b
or NSE levels and disease duration we used the non-parametric
correlation coefﬁcient Spearman’s Rho. Differences in CSF tau
protein levels between patients with disease duration above or
below the median (5 months) were compared using the Mann-
Witney test. For the second part of the study, we selected patients
who underwent more than one LP during the course of disease and
then compared the sensitivity and evolution of each of the CJD
markers. Differences in sensitivities were assessed using chi
2 test.
Results
One thousand ﬁve hundred and ﬁfty two samples
from sCJD patients were studied. The time of LP and
disease onset was available in 833 patients and the
median time from onset to LP was 3 months (range
0.1–84.5). The LP was performed during the ﬁrst stage
of the disease in 16% (n = 137), during the second
stage in 38% (n = 316), and in the ﬁnal stage in 46%
(n = 380). The median time from disease onset to LP
in patients who underwent the LP in the ﬁrst stage of
the disease was 1.9 months (range 0.1–10.2); 2.3
months (0.2–23.6) in patients that underwent the LP
in the second stage of the disease and 3.9 months
(0.7–84.5) for those in the third stage. The data on test
sensitivity for each marker stratiﬁed by the disease
stage are given in Table 1. The sensitivity of 14-3-3
tended to increase from the ﬁrst (88%) to the third
stage of the disease (91%), although these differences
were not statistically signiﬁcant. When stratifying by
codon 129 of PRNP, this trend became signiﬁcant in
the group of MV patients (p = 0.01).
Similar results were obtained for tau protein. There
were not signiﬁcant differences in the sensitivity of
tau or in the median level of tau across the three
disease stages (sensitivity of 81% in the ﬁrst stage and
90.5% in the third stage, n = 342). However, when
stratifying by codon 129, again the trend toward a
higher sensitivity through the disease stages became
signiﬁcant in the group of MV patients (p = 0.048)
(Table 1). There was a trend of a gradual increase of
tau levels in the MV patients, with the highest levels in
the last stage (median 1202 pg/mL in the ﬁrst stage,
1909 pg/mL in the second and 2601 in the third) and
in VV patients (median 5949 pg/mL in the second and
10422 in the third stage of the disease).
S100b levels were analysed in 297 samples, 37 in
the ﬁrst stage (12%), 112 in the second (38%), 148 in
the third (50%.). The disease stage clearly inﬂuenced
the S100b sensitivity with a signiﬁcant increase
(p = 0.01) in the latest stage (Table 1). The absolute
levels of S100b (Byk-Sangtec

kit) also increased
across the disease (p < 0.05).
NSE levels were assessed in 217 samples, and those
obtained in the last stage gave a signiﬁcantly higher
sensitivity (83%) when compared to the second stage
(67%, p = 0.01).
Levels of tau protein, S100b and NSE in CSF were
negatively correlated with disease duration (non-
parametric correlation coefﬁcient Spearman’s Rho =
tau innogenetics )20% (p < 0.001), S100b Byk-Sang-
tec

)17% (p = 0.002), S100b in house )18%
(p = 0.01), NSE Hoffman-la Roche

)21%
(p = 0.001)). Patients with a median disease duration
of 5 months or less had a median tau protein level of
6407 pg/mL (75–3623), whilst patients with a disease
duration of longer than 5 months had a median tau
protein level of 4411 pg/mL (75-47150), (Mann-Wit-
ney test p < 0.001).
Sixty-six out of 1552 (4%) sCJD patients under-
went more than one LP (at least two). The median
time lapse between the LPs was 6 weeks. Forty-two
(64%) of these cases were positive for 14-3-3 in the
ﬁrst LP (Figure 1). This value was different from the
sensitivity in the whole group (85%, p < 0.01). Fifty-
four (82%) of sCJD cases had a positive 14-3-3 in the
second sample (p = 0.025). Thirty-eight (57%) sCJD
patients had a positive 14-3-3 in both samples, and
58 (88%) patients had at least one positive 14-3-3.
Twenty sCJD patients (30%) changed their result for
14-3-3 in the second LP. Sixty-six percent of false
negative sCJD became positive but 9.5% of those
positive for 14-3-3 became negative in the second
LP.
The sensitivity of the other markers was also sig-
niﬁcantly lower in the ﬁrst LP when compared to the
whole group of sCJD (p < 0.05). However, the sensi-
tivity of these markers increased in the second sample
when compared to the ﬁrst, although not signiﬁcantly.
Eighty-one percent of sCJD cases had positive tau
protein levels in one of the two LPs, but only 61% of
cases had positive levels in both of them (Figure 1).
With respect to S100b and NSE, 66% and 70% of sCJD
patients had positive results in one of the two LPs and
53% and 33% in both of them, respectively.
We also found that the absolute levels of all three
quantitative markers tended to increase in the second
LP. This tendency was signiﬁcant for S100b (median
levels: 4.5 ng/ml (1–112) in the ﬁrst LP, median levels:
7 ng/ml (1–38) in the second; p = 0.027) (Figure 2).
In 39 out of 52 (75%) samples the levels of tau protein
were higher in the second LP than in the ﬁrst LP. NSE
levels were higher in the second LP when compared to
the ﬁrst in 32 out of 46 (70%) samples, and S100b
903levels were higher in the second LP when compared to
the ﬁrst in 27 out of 38 (71%) samples.
When we compared the characteristics of the sCJD
patients who underwent repeated LP to the overall
group of sCJD we found that these patients were
younger at onset (mean age: 61years SD 9.8 vs. 66
years SD 9.6) and more frequently under 40 years (6%
vs. 1%, p < 0.001). They had a longer disease duration
(mean: 12.8 months SD 8.7 vs. 7.9 months SD 7.8) and
were more frequently heterozygous at codon 129
(p < 0.001).
Discussion
Previous data about the inﬂuence of timing on the
levels of CSF markers for CJD diagnosis are contra-
dictory. The studies vary with respect to their meth-
odology and often only single patients were included
in the analysis. Jimi et al. [5] showed in a sequential
study that the levels of CJD markers increased during
the course of the disease and returned to normal or
mildly elevated levels in the terminal stage. Mollen-
hauer et al. [7] also discussed the difﬁculties of CJD
diagnosis in advanced cases presenting one sCJD case
that became 14-3-3 negative in the ﬁnal stage of the
disease. On the other hand, Giraud et al. [3] reported
an increase in the levels of 14-3-3 proteins during the
course of the disease in a limited number of sCJD
cases. Brandel et al. [2] performed a sequential study
in iatrogenic CJD, and observed that 14-3-3 was rarely
detectable within the ﬁrst 3 months of the disease but
always positive after 7 months associated with
aggravation of the disease and the occurrence of
dementia. The genotype at PRNP codon 129 inﬂu-
enced the timing of the rise of 14-3-3 in the CSF in
these cases. Kropp et al. [6] studied NSE levels in 16
sCJD patients with repeated LP. In 15 of them, NSE
levels were higher in the second LP with respect to the
ﬁrst, but no other markers were studied and the dis-
ease duration or the PRNP genotype were not analy-
sed. Finally, in a recent study, van Everbroeck et al.
[11] reported that in 42 sCJD patients the concen-
trations of 14-3-3 or tau protein were higher in the
middle point of the disease (arbitrarily determined
between the 25% and 85% of the total disease dura-
tion) than in the early or late stage.
In the framework of a multinational project, we
studied the inﬂuence of timing on the CSF marker
results in 833 sCJD patients. As the disease duration
Table 1 Sensitivity of markers in sporadic Creutzfeldt-Jakob disease at different disease stages, in the whole group and stratified by codon 129 PRNP genotype.
first stage  N second stage  N third stage  n p for trend*
Positive 14-3-3 87.6 120/137 88.0 278/316 91.3 347/380 Ns
MM 94.0 79/84 90.6 155/171 93.3 166/178 Ns
MV 60.0 15/25 69.8 37/53 89.2 58/65 0.01
VV 100.0 6/6 95.7 44/46 92.2 47/51 Ns
Positive tau 80.9 38/47 84.9 107/126 90.5 153/169 Ns
MM 83.9 26/31 88.2 60/68 92.9 79/85 Ns
MV 42.9 3/7 65.2 15/23 80.6 25/31 0.048
VV 100.0 1/1 100.0 17/17 96.0 24/25 Ns
Positive S100b 73.0 27/37 81.3 91/112 93.9 139/148 0.01
MM 78.6 22/28 81.4 48/59 97.1 68/70 0.02
MV 25.0 1/4 66.7 10/15 78.6 22/28 Ns
VV 0.0 0/1 89.5 17/19 100.0 23/23 Ns
Positive NSE 82.5 33/40 67.1 53/79 82.7 81/98 0.01
MM 86.7 26/30 68.9 31/45 84.9 45/53 0.02
MV 50.0 2/4 41.7 5/12 72.7 16/22 Ns
VV 0.0 0/1 76.9 10/13 87.5 14/16 Ns
* adjusted by country of origin, gender, disease duration, age of onset
  percentages
MM = methionine homozygous; MV = methionine/valine; VV = valine homozygous
NSE = neurone specific enolase. The cut-off value for tau was 1,300pg/ml; for S100b 4.2 ng/ml, for the Byk-Sangtec
 kit and 0.5 ng/ml for the, Non-commercial kit
used in the United Kingdom; and 35 ng/ml for the Hoffman La Roche
 kit and 25 ng/ml for Byk-Diasorin
, Byk-Sangtec
 and Wallac
 kits for NSE.
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Fig. 1 Sensitivity of markers for sporadic Creutzfeldt–Jakob disease diagnosis
in repeated lumbar punctures (LP) and combined results in both LP.
LP = lumbar puncture, + = positive, NSE = neurone specific enolase,
and = both LP+, or = either 1
st or 2
nd+
904differs among CJD patients, we decided to analyse
the inﬂuence of the stage of the disease, and not the
absolute time to the disease onset or death, on the
results of the CSF markers in order to avoid a bias
towards the results in patients with shorter disease
duration. On the other hand, in order to study the
inﬂuence of timing on the different PRNP genotypes
we also performed a stratiﬁed analysis by the PRNP
genotype.
Our study showed a tendency for the sensitivity of
all CSF markers to increase and for the absolute levels
of the quantitative markers to rise during the course
of the disease, using both the multivariate analysis
and the assessment of the repeated LPs. Thus, CSF
markers had the highest sensitivity at the third stage
of disease. The codon 129 PRNP genotype modiﬁed
this effect. The trend for a higher sensitivity of 14-3-3
and tau protein for sCJD diagnosis in the later stages
of disease only became signiﬁcant in the group of
codon 129 MV patients. In addition we found that
higher levels of tau protein were associated with a
shorter survival, similiar to the results of another
study, where CSF phosporylated tau protein levels
were analysed [10]. High levels of other brain-derived
proteins (S100b, NSE) were also signiﬁcantly associ-
ated with shorter survival. These brain-derived pro-
teins are released into the CSF as a result of cell
damage or death, and as such the levels of these
markers reﬂect the rate of cell death are probably
inversely related to disease duration. However, we
should admit that we did not assess separately the
sensitivity of the markers at very late stages of disease
and we cannot rule out a possible ﬁnal drop in sen-
sitivity, paired to a slower rate of cell death at the ﬁnal
stage.
In those sCJD patients who had more than one LP
performed, we found that the sensitivity of all CSF
markers increased in the second LP when compared
to the ﬁrst LP. In more than 70% of all sCJD cases
tested the absolute levels of the three quantitative
markers also increased in the second LP. Sporadic
CJD patients who underwent a second LP differed
from the whole group, in that they were younger, had
a longer disease duration and were more frequently
heterozygous for PRNP codon 129 when compared to
the whole group. These characteristics made them a
more difﬁcult group to diagnose and may explain why
a second LP was performed. In this group of atypical
sCJD patients a second LP increased the 14-3-3 sen-
sitivity by 18%.
In conclusion, in our study we found that the
sensitivity of the CSF markers for sCJD diagnosis
increased during disease progression and that this
was modulated by the codon 129 genotype. High
levels of CSF brain-derived proteins were associated
with a shorter survival. A negative CSF 14-3-3 result
Second test First test Second test First test
Second test First test
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1
Fig. 2 Levels of quantitative markers in repeated
lumbar punctures.
1Differences between median
levels were not significant.
2THe median S100b levels
were different (p = 0.027). *Byk-Sangtec kit
905in the early stages should be interpreted with caution,
especially in MV patients. Although performing a
second LP is not usual clinical practice for the
diagnosis of CJD, it may be useful to perform a second
LP, 4–6 weeks after the initial one, in young patients,
those with long clinical course or MV genotype.
j Acknowledgements We thank all physicians in the participating
countries for sending us the cerebrospinal fluid and blood samples
and for providing pertinent clinical and neuropathological data on
those patients. We thank Jolanthe Zellner for her coordinative work
and Esther Croes for database management at the initial stages of
the project. The collaborative study was funded by grants from the
European Commission (EC) (QLG3-CT-2002-81606 to I. Zerr).
The national studies were supported in Greece by the Greek Min-
istry of Health, through KEEL (Center for Control of Infectious
Diseases), in Italy by the Ministry of Health and the Instituto Su-
periore di Sanita `, in the Netherlands by the Dutch Ministry of
Health, Welfare and Sports, in Slovakia by Ministry of Health and
European Commission (SEEC-CJD project), in Spain by a grant
from the Ministerio de Ciencia y Tecnologı ´a (MCyT EET 2001/
2216) and Spanish Ministerio de Sanidad y Consumo, grant num-
ber DGVI 1312/04-1, in Switzerland by Bundesamt fu ¨r Gesundheit,
Bern (NRPE-BAG contracts n 03.001297and n 04.002363), in
United Kingdom by the Department of Health and the Scottish
Home Office Department of Health and in Germany by the Bun-
desministerium fu ¨r Gesundheit und Soziale Sicherung (BMGS) (GZ:
325-4471-02/15) and by the Bundesministerium fu ¨r Bildung und
Forschung (BMBF) (KZ: 0312720 and 01GI0301 to I.Z). Raquel
Sanchez-Valle is a recipient of a post-residency grant from Instituto
de Salud Carlos III, Madrid, Spain. Pascual Sanchez-Juan was
supported by the postMIR grant Wenceslao Lopez Albo from the
IFIMAV Institute of the Fundacio ´nP u ´blica Marque ´s de Valdecilla.
References
1. Beaudry P, Cohen P, Brandel JP, et al.
(1999) 14-3-3 protein, neuron-speciﬁc
enolase, and S100b protein in cerebro-
spinal ﬂuid of patients with Creutz-
feldt-Jakob disease. Dement Geriatr
Cogn Disord 10(1):40–6
2. Brandel JP, Peoc’h K, Beaudry P, et al.
(2001) 14-3-3 protein cerebrospinal
ﬂuid detection in human growth hor-
mone-treated Creutzfeldt-Jakob disease
patients. Ann Neurol 49(2):257–60
3. Giraud P, Biacabe A-G, Chazot G, et al.
(2002) Increased detection of 14-3-3
protein in Cerebrospinal ﬂuid in Spo-
radic Creutzfeldt-Jakob disease during
the disease course. Eur Neurol 48:218–
221
4. Green AJE, Keir G, Thompson EJ
(1997) A speciﬁc and sensitive ELISA
for measuring S100b in the cerebro-
spinal ﬂuid. J Immmunol Methods
205:35–41
5. Jimi T, Wakayama Y, Shibuya S, et al.
(1992) High levels of nervous system-
speciﬁc proteins in cerebrospinal ﬂuid
in patients with early stage Creutzfeldt-
Jakob disease. Clin Chim Acta 211:37–
46
6. Kropp S, Zerr I, Schulz-Schaeffer WJ,
et al. (1999) Increase of neuron-speciﬁc
enolase in patients with Creutzfeldt-
Jakob disease. Neurosc Lett 261(1–
2):124–6
7. Mollenhauer B, Seraﬁn S, Zerr I, et al.
(2003) Diagnostic problems during late
course in Creutzfeldt-Jakob disease. J
Neurol 250:629–630
8. Otto M, Wiltfang J, Cepek L, et al.
(2002) Tau protein and 14-3-3 protein
in the differential diagnosis of Creutz-
feldt-Jakob disease. Neurology 58:192–
197
9. Sa ´nchez-Juan P, Green A, Ladogana A,
et al. (2006) CSF tests in the differential
diagnosis of Creutzfeldt-Jakob disease.
Neurology 67(4):637–643
10. Van Everbroeck B, Green AJ, Vanm-
echelen E, et al. (2002) Phosphorylated
tau in cerebrospinal ﬂuid as a marker
for Creutzfeldt-Jakob disease. J Neurol
Neurosurg Psychiatr 73(1):79–81
11. Van Everbroeck B, Quolin S, Boons J,
et al. (2003) A prospective study of CSF
markers in 250 patients with possible
Creutzfeldt-Jakob disease. J Neurol
Neurosurg Psychiatry 74:1210–1214
12. WHO. Human transmissible spongi-
form encephalopathies (1998) Wkly
Epidemiol Rec 73:361–72
13. Zerr I, Bodemer M, Ra ¨cker S, et al.
(1995) Cerebrospinal ﬂuid concentra-
tion of neuron-speciﬁc enolase in
diagnosis of Creutzfeldt-Jakob disease.
Lancet 345:1609–1610
14. Zerr I, Pocchiari M, Collins S, et al.
(2000) Analysis of EEG and CSF 14-3-3
proteins as aids to the diagnosis of
Creutzfeldt-Jakob disease. Neurology
55:811–815
906